Literature DB >> 33588112

Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes.

Meredith A Ray1, Carrie Fehnel2, Olawale Akinbobola2, Nicholas R Faris3, Meghan Taylor2, Alicia Pacheco2, Matthew P Smeltzer1, Raymond U Osarogiagbon4.   

Abstract

INTRODUCTION: The adverse prognostic impact of poor pathologic nodal staging has stimulated efforts to heighten awareness of the problem through guidelines, without guidance on processes to overcome it. We compared heightened awareness (HA) of nodal staging quality versus a lymph node collection kit.
METHODS: We categorized curative-intent lung cancer resections from 2009 to 2020 in a population-based, nonrandomized stepped-wedge implementation study of both interventions, into preintervention baseline, HA, and kit subcohorts. We used differences in proportion and hazard ratios across the subcohorts to estimate the effect of the interventions on poor quality (nonexamination of nodes [pNX] or nonexamination of mediastinal lymph nodes) and attainment of quality recommendations of the National Comprehensive Cancer Network, the Commission on Cancer, and the proposed complete resection definition of the International Association for the Study of Lung Cancer across the three cohorts.
RESULTS: Of 3734 resections, 39% were preintervention, 40% kit, and 21% HA cases. Cohort proportions were the following: pNX, 11% (baseline) versus 0% (kit) versus 9% (HA); nonexamination of mediastinal lymph nodes, 27% versus 1% versus 22%; Commission on Cancer benchmark attainment, 14% versus 77% versus 30%; International Association for the Study of Lung Cancer-defined complete resection, 11% versus 58% versus 24%; National Comprehensive Cancer Network attainment, 23% versus 79% versus 35% (p < 0.001 for all, except pNX rate baseline versus HA). Survival rate was significantly higher for both interventions compared with baseline (p < 0.0001).
CONCLUSIONS: Resections with HA or the kit significantly improved surgical quality and outcomes, but the kit was more effective. We propose to conduct a prospective, institutional cluster-randomized clinical trial comparing both interventions.
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  American College of Surgeons Operative Standard 5.8; Heightened awareness; Lymph node specimen collection kit; Quality of care; Surgical resection

Mesh:

Year:  2021        PMID: 33588112      PMCID: PMC8084985          DOI: 10.1016/j.jtho.2021.01.1618

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  32 in total

1.  Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria.

Authors:  Raymond U Osarogiagbon; Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Raymond S Signore; Laura M McHugh; Paul Levy; Lynn Wiggins; Vishal Sachdev; Edward T Robbins
Journal:  Ann Thorac Surg       Date:  2017-03-31       Impact factor: 4.330

2.  Completeness of lung cancer surgery: is mediastinal dissection common practice?

Authors:  Ad F Verhagen; Micha C J Schoenmakers; Wout Barendregt; Hans Smit; Wim-Jan van Boven; Monica Looijen; Erik H F M van der Heijden; Henry A van Swieten
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-18       Impact factor: 4.191

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.

Authors:  John G Edwards; Kari Chansky; Paul Van Schil; Andrew G Nicholson; Souheil Boubia; Elisabeth Brambilla; Jessica Donington; Françoise Galateau-Sallé; Hans Hoffmann; Maurizio Infante; Mirella Marino; Edith M Marom; Jun Nakajima; Marcin Ostrowski; William D Travis; Ming-Sound Tsao; Yasushi Yatabe; Dorothy J Giroux; Lynn Shemanski; John Crowley; Marc Krasnik; Hisao Asamura; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2019-11-13       Impact factor: 15.609

5.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

Review 7.  Complete resection in lung cancer surgery: proposed definition.

Authors:  Ramón Rami-Porta; Christian Wittekind; Peter Goldstraw
Journal:  Lung Cancer       Date:  2005-07       Impact factor: 5.705

8.  Nonexamination of lymph nodes and survival after resection of non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Xinhua Yu
Journal:  Ann Thorac Surg       Date:  2013-07-30       Impact factor: 4.330

9.  Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Obiageli Ogbata; Xinhua Yu
Journal:  Ann Thorac Surg       Date:  2013-11-20       Impact factor: 4.330

10.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Raymond U Osarogiagbon
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

View more
  2 in total

1.  Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).

Authors:  Kenneth L Kehl; David Zahrieh; Ping Yang; Shauna L Hillman; Angelina D Tan; Jacob M Sands; Geoffrey R Oxnard; Erin A Gillaspie; Dennis Wigle; Shakun Malik; Thomas E Stinchcombe; Suresh S Ramalingam; Karen Kelly; Ramaswamy Govindan; Sumithra J Mandrekar; Raymond U Osarogiagbon; David Kozono
Journal:  JAMA Oncol       Date:  2022-05-01       Impact factor: 33.006

2.  Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Carrie Fehnel; Olawale Akinbobola; Andrea Saulsberry; Meghan Meadows-Taylor; Alicia Pacheco; Meredith Ray; Raymond U Osarogiagbon
Journal:  JTO Clin Res Rep       Date:  2021-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.